Skip to main content
Autobound logo

Johnson & Johnson news and events in 2026

At Johnson & Johnson, we believe health is everything. As a focused healthcare company, with expertise in Innovative Medicine and MedTech, we’re empowered to tackle the world’s toughest health challenges, innovate through science and technology, and transform patient care.

Public (JNJ)Pharmaceutical Manufacturing10,000+ employeesjnj.comLinkedIn

Dated updates
79
Last event
Sep 29, 2026
Open rolesSnapshot Sep 29, 2026
841
Latest SEC filing
Aug 4, 2026

Overview

Johnson & Johnson by topic

Latest events

Latest Johnson & Johnson events

All Johnson & Johnson news →
  1. Launch
    A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple...Johnson & Johnson announced new data from its Phase 3 MajesTEC-3 study for TECVAYLI® (teclistamab) combined with daratumumab, showing durable disease control and prolonged survival in patients with relapsed or refractory multiple myeloma.
    globenewswire.com
  2. In development
    Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic...Johnson & Johnson announced its drug TREMFYA® (guselkumab) met primary and major secondary endpoints in its Phase 4 STAR study for treating adults with active psoriatic arthritis and axial involvement.
    prnewswire.com
  3. In development
    New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term...Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study for its combination therapy of TECVAYLI® and DARZALEX FASPRO® for relapsed or refractory multiple myeloma, showing sustained disease control and survival.
    prnewswire.com
  4. Launch
    European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptideJohnson & Johnson has received approval from the European Commission for its new oral peptide drug, ICOTYDE™ (icotrokinra), for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents.
    globenewswire.com
  5. In development
    Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future GrowthJohnson & Johnson's emerging therapy, ICOTYDE (icotrokinra), is expected to significantly reshape the Psoriatic Arthritis (PsA) market.
    globenewswire.com
  6. Spin-off
    Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal$20B · With DePuy Synthes
    theglobeandmail.com
  7. Layoff
    Johnson & Johnson Stock Reacts to New Earnings Estimates and Job Cut Signal87 roles (reported)
    ad-hoc-news.de
  8. Investment
    Tempo Therapeutics Raises $14.5 Million To Advance Regenerative Tissue Technology Toward CommercializationJohnson & Johnson, through its innovation arm JJDC, participated in a $14.5 million financing round for Tempo Therapeutics.
    pulse2.com
  9. In development
    CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapyJohnson & Johnson's drug TECVAYLI® (teclistamab) received a recommendation for approval from the European Medicines Agency's CHMP for an extended indication to treat adult patients with relapsed/refractory multiple myeloma who have had at least one prior therapy.
    globenewswire.com
  10. Earnings
    Johnson & Johnson stock gains as guidance points to 2026 revenue above USD 100 billionJohnson & Johnson reported adjusted EPS of USD 2.90 on revenue of USD 25.31 billion in its most recent quarter.
    ad-hoc-news.de

Showing 10 of 30 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Johnson & Johnson with the Signal API

One POST /v1/companies/enrich call with jnj.com returns every signal type for Johnson & Johnson, each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'

Same industry

Companies related to Johnson & Johnson

Johnson & Johnson questions

What is the latest news on Johnson & Johnson?
On Sep 28, 2026, globenewswire.com reported: A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple. This page tracks 30 news events for Johnson & Johnson since Jul 14, 2026, each with a date and a source link.
What is going on with Johnson & Johnson?
In the 90 days to Sep 30, 2026, Autobound tracked 30 news events, 1 10-Q filing, 2 8-K filings, 4 hiring snapshots, 1 reported layoff round, 1 deal, 31 signals for Johnson & Johnson. The newest story is from Sep 28, 2026 (Launch), reported by globenewswire.com.
Is Johnson & Johnson laying off employees?
ad-hoc-news.de reported on Sep 21, 2026: Johnson & Johnson Stock Reacts to New Earnings Estimates and Job Cut Signal. Autobound lists 1 reported layoff round for Johnson & Johnson. Each row states what its source reported, not a confirmed total.
Has Johnson & Johnson announced any acquisitions?
The latest deal story is from Jul 30, 2026. es-us.finanzas.yahoo.com reported: Johnson & Johnson Partners with Sail Biomedicines and Gains Purchase Option. The acquisitions page lists 1 deal with a source for each.
What else does Autobound track for Johnson & Johnson?
Beyond news and filings, Autobound lists 44+ signals for Johnson & Johnson from 6 sources: Glassdoor (15+), LinkedIn (11), Patents (10), Podcasts (3), Web traffic (3), Reddit (2). See the Johnson & Johnson signals page for the dated list.
Is Johnson & Johnson hiring right now?
Yes. As of Sep 29, 2026, Johnson & Johnson had 841 open roles, and Sales had the most with 94.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →